Initially synthesized by chemist Wayne E. Kenney, BAY 38-7271 (also known as KN 38-7271) is a pharmaceutical compound developed by Bayer AG. This drug is a cannabinoid receptor agonist, exhibiting analgesic and neuroprotective properties. BAY 38-7271 is primarily employed in scientific research and has shown promise for potential applications in treating traumatic brain injury. In animal studies, BAY 38-7271 has demonstrated its status as a full agonist, possessing similar potency to CP 55,940. It exhibits a notable affinity for CB1 and CB2 receptors, with Ki values measured at 2.91nM for CB1 and 4.24nM for CB2. This intriguing pharmaceutical was initially licensed to KeyNeurotek Pharmaceuticals for clinical development and progressed to Phase II trials in 2008. However, further development of BAY 38-7271 has halted since then.
BAY 38-7271, also known as KN 38-7271, is a pharmaceutical compound developed by Bayer AG. It acts as a cannabinoid receptor agonist and is known for its analgesic and neuroprotective effects.
What are the proposed uses of BAY 38-7271?
BAY 38-7271 has been studied for potential applications in treating traumatic brain injury. Its neuroprotective properties make it a candidate for addressing brain injuries.
How potent is BAY 38-7271 as a cannabinoid receptor agonist?
In animal studies, BAY 38-7271 has been identified as a full agonist with a potency similar to CP 55,940, another synthetic cannabinoid.
What is the receptor affinity of BAY 38-7271?
BAY 38-7271 exhibits significant affinity for CB1 and CB2 receptors, with Ki values of approximately 2.91nM at CB1 and 4.24nM at CB2.
Who is developing BAY 38-7271 for clinical use?
Initially licensed to KeyNeurotek Pharmaceuticals for clinical development, BAY 38-7271 underwent Phase II trials in 2008. However, limited information is available about its current status in clinical development.
Is BAY 38-7271 available for medical use or research?
BAY 38-7271 is primarily used for scientific research and has not been widely adopted for medical treatment. Its status in clinical development may have evolved since the Phase II trials.
Highly Selective Agonist: BAY 38-7271 is a highly selective and potent cannabinoid receptor agonist. It has been developed with a focus on its potential in the treatment of traumatic brain injury.
Neuroprotective Effects: Research has shown that BAY 38-7271 exhibits neuroprotective properties, making it a candidate for mitigating brain damage and brain edema associated with traumatic injuries.
Traumatic Brain Injury: BAY 38-7271’s primary application is in the field of traumatic brain injury. It has demonstrated the ability to reduce brain edema, which is a significant concern in such injuries.
Clinical Development: The compound was initially licensed to KeyNeurotek Pharmaceuticals for clinical development. It underwent Phase I trials, reporting positive data. However, its current status in clinical development may require further investigation.
Diarylether Sulfonylester: BAY 38-7271 is characterized as a diarylether sulfonylester compound. Its pharmacological properties, including its potent cannabinoid receptor agonism, have been a subject of study.
Discriminative Stimulus Effects: BAY 38-7271 has also been investigated for its discriminative stimulus effects. This research provides insights into its potential psychoactive properties.